Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 265171
  • calendar_today Published On: Jan, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size is estimated to be worth US$ 1428.3 million in 2021 and is forecast to a readjusted size of USD 2826.1 million by 2028 with a CAGR of 10.2% during review period. Hospitals Pharmacy accounting for % of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While XIFAXAN segment is altered to a % CAGR between 2022 and 2028.

Global key manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs include Bausch Health, Allergan, Sebela Pharmaceuticals, Astellas Pharmaceuticals, and Amneal Pharms, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is split by Type and by Sales Channel. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Sales Channel in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

XIFAXAN

Viberzi

Lotronex

Other

Market segment by Sales Channel can be divided into

Hospitals Pharmacy

Retail Pharmacy

Other

The key market players for global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market are listed below:

Bausch Health

Allergan

Sebela Pharmaceuticals

Astellas Pharmaceuticals

Amneal Pharms

Pharscin Pharma

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, with price, sales, revenue and global market share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs from 2019 to 2022.

Chapter 3, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, sales channel, from 2017 to 2028.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market forecast, by regions, type and sales channel, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.

Chapter 13, 14, and 15, to describe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Introduction

1.2 Market Analysis by Type

1.2.1 Overview: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type: 2017 Versus 2021 Versus 2028

1.2.2 XIFAXAN

1.2.3 Viberzi

1.2.4 Lotronex

1.2.5 Other

1.3 Market Analysis by Sales Channel

1.3.1 Overview: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel: 2017 Versus 2021 Versus 2028

1.3.2 Hospitals Pharmacy

1.3.3 Retail Pharmacy

1.3.4 Other

1.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size & Forecast

1.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Value (2017 & 2021 & 2028)

1.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume (2017-2028)

1.4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (2017-2028)

1.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity Analysis

1.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Total Production Capacity (2017-2028)

1.5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity by Geographic Region

1.6 Market Drivers, Restraints and Trends

1.6.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Drivers

1.6.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints

1.6.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Trends Analysis

2 Manufacturers Profiles

2.1 Bausch Health

2.1.1 Bausch Health Details

2.1.2 Bausch Health Major Business

2.1.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services

2.1.4 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2 Allergan

2.2.1 Allergan Details

2.2.2 Allergan Major Business

2.2.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services

2.2.4 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3 Sebela Pharmaceuticals

2.3.1 Sebela Pharmaceuticals Details

2.3.2 Sebela Pharmaceuticals Major Business

2.3.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services

2.3.4 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4 Astellas Pharmaceuticals

2.4.1 Astellas Pharmaceuticals Details

2.4.2 Astellas Pharmaceuticals Major Business

2.4.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services

2.4.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5 Amneal Pharms

2.5.1 Amneal Pharms Details

2.5.2 Amneal Pharms Major Business

2.5.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services

2.5.4 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6 Pharscin Pharma

2.6.1 Pharscin Pharma Details

2.6.2 Pharscin Pharma Major Business

2.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services

2.6.4 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Breakdown Data by Manufacturer

3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)

3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)

3.3 Key Manufacturer Market Position in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

3.4 Market Concentration Rate

3.4.1 Top 3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer Market Share in 2021

3.4.2 Top 6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer Market Share in 2021

3.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity by Company: 2021 VS 2022

3.6 Manufacturer by Geography: Head Office and Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Site

3.7 New Entrant and Capacity Expansion Plans

3.8 Mergers & Acquisitions

4 Market Analysis by Region

4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region

4.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Region (2017-2028)

4.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2017-2028)

4.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028)

4.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028)

4.4 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028)

4.5 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028)

4.6 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028)

5 Market Segment by Type

5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Type (2017-2028)

5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2017-2028)

5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2017-2028)

6 Market Segment by Sales Channel

6.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Sales Channel (2017-2028)

6.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2017-2028)

6.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel (2017-2028)

7 North America by Country, by Type, and by Sales Channel

7.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2028)

7.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2028)

7.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country

7.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Country (2017-2028)

7.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2028)

7.3.3 United States Market Size and Forecast (2017-2028)

7.3.4 Canada Market Size and Forecast (2017-2028)

7.3.5 Mexico Market Size and Forecast (2017-2028)

8 Europe by Country, by Type, and by Sales Channel

8.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2028)

8.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2028)

8.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country

8.3.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Country (2017-2028)

8.3.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2028)

8.3.3 Germany Market Size and Forecast (2017-2028)

8.3.4 France Market Size and Forecast (2017-2028)

8.3.5 United Kingdom Market Size and Forecast (2017-2028)

8.3.6 Russia Market Size and Forecast (2017-2028)

8.3.7 Italy Market Size and Forecast (2017-2028)

9 Asia-Pacific by Region, by Type, and by Sales Channel

9.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2028)

9.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2028)

9.3 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region

9.3.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Region (2017-2028)

9.3.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2017-2028)

9.3.3 China Market Size and Forecast (2017-2028)

9.3.4 Japan Market Size and Forecast (2017-2028)

9.3.5 Korea Market Size and Forecast (2017-2028)

9.3.6 India Market Size and Forecast (2017-2028)

9.3.7 Southeast Asia Market Size and Forecast (2017-2028)

9.3.8 Australia Market Size and Forecast (2017-2028)

10 South America by Region, by Type, and by Sales Channel

10.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2028)

10.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2028)

10.3 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country

10.3.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Country (2017-2028)

10.3.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2028)

10.3.3 Brazil Market Size and Forecast (2017-2028)

10.3.4 Argentina Market Size and Forecast (2017-2028)

11 Middle East & Africa by Country, by Type, and by Sales Channel

11.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2028)

11.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2028)

11.3 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country

11.3.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Country (2017-2028)

11.3.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2028)

11.3.3 Turkey Market Size and Forecast (2017-2028)

11.3.4 Egypt Market Size and Forecast (2017-2028)

11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)

11.3.6 South Africa Market Size and Forecast (2017-2028)

12 Raw Material and Industry Chain

12.1 Raw Material of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs and Key Manufacturers

12.2 Manufacturing Costs Percentage of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

12.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Process

12.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Typical Distributors

13.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Typical Customers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Research Process and Data Source

15.3 Disclaimer

List of Tables

Table 1. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028

Table 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel, (USD Million), 2017 & 2021 & 2028

Table 3. Bausch Health Basic Information, Manufacturing Base and Competitors

Table 4. Bausch Health Major Business

Table 5. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services

Table 6. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 7. Allergan Basic Information, Manufacturing Base and Competitors

Table 8. Allergan Major Business

Table 9. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services

Table 10. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 11. Sebela Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 12. Sebela Pharmaceuticals Major Business

Table 13. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services

Table 14. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 15. Astellas Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table 16. Astellas Pharmaceuticals Major Business

Table 17. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services

Table 18. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 19. Amneal Pharms Basic Information, Manufacturing Base and Competitors

Table 20. Amneal Pharms Major Business

Table 21. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services

Table 22. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 23. Pharscin Pharma Basic Information, Manufacturing Base and Competitors

Table 24. Pharscin Pharma Major Business

Table 25. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services

Table 26. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)

Table 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)

Table 29. Market Position of Manufacturers in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021

Table 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity by Company, (K Units): 2020 VS 2021

Table 31. Head Office and Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Site of Key Manufacturer

Table 32. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs New Entrant and Capacity Expansion Plans

Table 33. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Mergers & Acquisitions in the Past Five Years

Table 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2017-2022) & (K Units)

Table 35. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2023-2028) & (K Units)

Table 36. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2017-2022) & (USD Million)

Table 37. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2023-2028) & (USD Million)

Table 38. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)

Table 39. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2023-2028) & (K Units)

Table 40. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2017-2022) & (USD Million)

Table 41. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2023-2028) & (USD Million)

Table 42. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2017-2022) & (USD/Unit)

Table 43. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2023-2028) & (USD/Unit)

Table 44. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)

Table 45. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2023-2028) & (K Units)

Table 46. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2017-2022) & (USD Million)

Table 47. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2023-2028) & (USD Million)

Table 48. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel (2017-2022) & (USD/Unit)

Table 49. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel (2023-2028) & (USD/Unit)

Table 50. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2022) & (K Units)

Table 51. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2023-2028) & (K Units)

Table 52. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2022) & (USD Million)

Table 53. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2023-2028) & (USD Million)

Table 54. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)

Table 55. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2023-2028) & (K Units)

Table 56. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)

Table 57. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2023-2028) & (K Units)

Table 58. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2022) & (K Units)

Table 59. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2023-2028) & (K Units)

Table 60. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2022) & (USD Million)

Table 61. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2023-2028) & (USD Million)

Table 62. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)

Table 63. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2023-2028) & (K Units)

Table 64. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)

Table 65. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2023-2028) & (K Units)

Table 66. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2017-2022) & (K Units)

Table 67. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2023-2028) & (K Units)

Table 68. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2017-2022) & (USD Million)

Table 69. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2023-2028) & (USD Million)

Table 70. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)

Table 71. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2023-2028) & (K Units)

Table 72. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)

Table 73. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2023-2028) & (K Units)

Table 74. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2022) & (K Units)

Table 75. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2023-2028) & (K Units)

Table 76. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2022) & (USD Million)

Table 77. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2023-2028) & (USD Million)

Table 78. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)

Table 79. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2023-2028) & (K Units)

Table 80. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)

Table 81. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2023-2028) & (K Units)

Table 82. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2017-2022) & (K Units)

Table 83. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2023-2028) & (K Units)

Table 84. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2017-2022) & (USD Million)

Table 85. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2023-2028) & (USD Million)

Table 86. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)

Table 87. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2023-2028) & (K Units)

Table 88. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)

Table 89. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2023-2028) & (K Units)

Table 90. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Raw Material

Table 91. Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Raw Materials

Table 92. Direct Channel Pros & Cons

Table 93. Indirect Channel Pros & Cons

Table 94. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Typical Distributors

Table 95. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Typical Customers

List of Figures

Figure 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Picture

Figure 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type in 2021

Figure 3. XIFAXAN

Figure 4. Viberzi

Figure 5. Lotronex

Figure 6. Other

Figure 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel in 2021

Figure 8. Hospitals Pharmacy

Figure 9. Retail Pharmacy

Figure 10. Other

Figure 11. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028

Figure 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Forecast (2017-2028) & (USD Million)

Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (2017-2028) & (K Units)

Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (2017-2028) & (USD/Unit)

Figure 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity (2017-2028) & (K Units)

Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity by Geographic Region: 2022 VS 2028

Figure 17. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Drivers

Figure 18. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints

Figure 19. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Trends

Figure 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturer in 2021

Figure 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Manufacturer in 2021

Figure 22. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021

Figure 23. Top 3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer (Revenue) Market Share in 2021

Figure 24. Top 6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer (Revenue) Market Share in 2021

Figure 25. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2017-2028)

Figure 26. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2017-2028)

Figure 27. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (USD Million)

Figure 28. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (USD Million)

Figure 29. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (USD Million)

Figure 30. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (USD Million)

Figure 31. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2017-2028) & (USD Million)

Figure 32. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2028)

Figure 33. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2017-2028)

Figure 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2017-2028) & (USD/Unit)

Figure 35. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2028)

Figure 36. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2017-2028)

Figure 37. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel (2017-2028) & (USD/Unit)

Figure 38. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2028)

Figure 39. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2028)

Figure 40. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2017-2028)

Figure 41. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2017-2028)

Figure 42. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 43. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 44. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 45. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2028)

Figure 46. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2028)

Figure 47. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2017-2028)

Figure 48. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2017-2028)

Figure 49. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 50. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. United Kingdom Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2017-2028)

Figure 55. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2028)

Figure 56. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2017-2028)

Figure 57. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2017-2028)

Figure 58. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2028)

Figure 65. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2028)

Figure 66. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2017-2028)

Figure 67. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2017-2028)

Figure 68. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2028)

Figure 71. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2028)

Figure 72. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2017-2028)

Figure 73. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2017-2028)

Figure 74. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 78. Manufacturing Cost Structure Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in 2021

Figure 79. Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

Figure 80. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain

Figure 81. Sales Channel: Direct Channel vs Indirect Channel

Figure 82. Methodology

Figure 83. Research Process and Data Source